Immunovant provides Phase 3 update for batoclimab in myasthenia gravis

Immunovant, Inc.

Corporate webcast held Jan 5, 2022; presentation focuses on Phase 3 development of batoclimab.
Batoclimab is the company's lead anti-FcRn antibody candidate for myasthenia gravis.
No specific clinical data or milestones were disclosed in the filing or attached presentation.
Update may include trial design, enrollment status, or regulatory timeline; details not provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.